141 related articles for article (PubMed ID: 30279886)
1. Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry disease.
Kaneda T; Takeda M; Suematsu T; Yamamoto R; Takata M; Higashikata T; Ino H; Tsujibata A; Hayashi K; Fujino N; Kawashiri MA
J Cardiol Cases; 2018 May; 17(5):178-181. PubMed ID: 30279886
[TBL] [Abstract][Full Text] [Related]
2. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
4. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy in two patients with classic Fabry disease from the same family tree: Two case reports.
Harigane Y; Morimoto I; Suzuki O; Temmoku J; Sakamoto T; Nakamura K; Machii K; Miyata M
World J Clin Cases; 2023 May; 11(15):3542-3551. PubMed ID: 37383915
[TBL] [Abstract][Full Text] [Related]
6. Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy.
Hongo K; Harada T; Fukuro E; Kobayashi M; Ohashi T; Eto Y
Mol Genet Metab Rep; 2020 Sep; 24():100623. PubMed ID: 32714835
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
8. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.
Hongo K; Ito K; Date T; Anan I; Inoue Y; Morimoto S; Ogawa K; Kawai M; Kobayashi H; Kobayashi M; Ida H; Ohashi T; Taniguchi I; Yoshimura M; Eto Y
Mol Genet Metab; 2018 Jun; 124(2):143-151. PubMed ID: 29747997
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy.
Maurizi N; Nowak A; Gruner C; Namdar M; Schmied C; Porretta AP; Barbey G; Monzambani V; Monney P; Barbey F
Heart; 2024 May; ():. PubMed ID: 38749654
[TBL] [Abstract][Full Text] [Related]
13. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
14. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
Beck M; Hughes D; Kampmann C; Larroque S; Mehta A; Pintos-Morell G; Ramaswami U; West M; Wijatyk A; Giugliani R;
Mol Genet Metab Rep; 2015 Jun; 3():21-7. PubMed ID: 26937390
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.
Moore DF; Ries M; Forget EL; Schiffmann R
Pharmacoeconomics; 2007; 25(3):201-8. PubMed ID: 17335306
[TBL] [Abstract][Full Text] [Related]
19. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
